Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …

Multi-drug resistance (MDR) in cancer cells, either intrinsic or acquired through various
mechanisms, significantly hinders the therapeutic efficacy of drugs. Typically, the reduced …

The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy of T
cell progenitors, known to be a heterogeneous disease in pediatric and adult patients. Here …

The glucocorticoid receptor (GR) regulates gene expression, governing aspects of
homeostasis, but is also involved in cancer. Pharmacological GR activation is frequently …

Blinatumomab is an efficacious immunotherapeutic agent in B cell acute lymphoblastic
leukemia (B-ALL). However, the pharmacogenomic basis of leukemia response to …

The CRISPR genome editing technology has revolutionized the way gene function is
studied. Genome editing can be achieved in single genes or for thousands of genes …

Resistance to glucocorticoids (GC) is associated with an increased risk of relapse in B-cell
progenitor acute lymphoblastic leukemia (BCP-ALL). Performing transcriptomic and single …

Glucocorticoid receptor (GR) is a key homeostatic regulator involved in governing immune
response, neuro-integration, metabolism and lung function. In conjunction with its pivotal …